Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

NCT01280929 is registered in ClinicalTrials.gov with José Cunha-Vaz as lead sponsor.

NCT NCT01280929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
Lead sponsor
José Cunha-Vaz
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
December 31, 2013
Enrollment
54 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

high risk proliferative diabetic retinopathy